Middle East And Africa Prophylaxis Of Organ Rejection Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2022 –2029 |
 시장 규모(기준 연도) |
USD 59.81 Million |
 시장 규모(예측 연도) |
USD 69.23 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>중동 및 아프리카 장기 거부 반응 예방 시장, 원인(역학적 노출, 항균 예방, 기타 병원균에 대한 예방 및 기타), 치료(외래 면역억제제, 입원 면역억제제 및 기타), 투여 경로(경구, 정맥 주사), 장기(신장, 간, 심장, 폐, 기타), 환자 유형(소아, 성인), 최종 사용자(병원, 클리닉, 홈 헬스케어 및 기타), 유통 채널(직접 입찰, 약국 및 기타), 국가(사우디 아라비아, 남아프리카, 이스라엘, 쿠웨이트, UAE 및 중동 및 아프리카의 나머지 지역), 시장 동향 및 2029년까지의 예측.
시장 분석 및 통찰력: 중동 및 아프리카 장기 거부 예방 시장
중동 및 아프리카 장기 거부 예방 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 2.0%의 CAGR로 성장하고 있으며 2021년의 5,981만 달러에서 2029년까지 6,923만 달러에 도달할 것으로 예상된다고 분석합니다. 장기 이식의 유병률 증가와 면역 억제제 사용 증가는 예측 기간 동안 시장 수요를 촉진하는 주요 원동력이 될 가능성이 높습니다.
예방이라는 용어는 질병을 예방하기 위해 제공되는 치료 또는 취해지는 조치를 의미합니다. 장기 거부의 예방은 약물을 사용하여 장기 거부를 예방하는 것을 말합니다. 이식을 받는 환자는 이식편 생존을 보장하기 위해 거부 예방을 위한 면역 억제 요법을 유지해야 합니다. 이식 거부는 이식 수혜자의 면역이 칼시뉴린 억제제, mTOR 억제제, 항대사제 및 코르티코스테로이드를 사용하여 구현되는 과정입니다. 치료제는 장기 이식의 단기적 결과를 개선하지만 특정 개선은 개선합니다. 고형 장기 이식을 받은 수혜 환자는 항거부 약물을 복용해야 합니다. 이는 면역 체계가 이식된 장기를 파괴하기 때문입니다.
중동 및 아프리카 장기 거부 예방 시장 성장을 담당하는 주요 요인은 장기 이식의 유행 증가, 수술 절차 증가, 수혜자 인구 증가 및 제품 출시입니다. 그러나 시장을 억제할 것으로 예상되는 요인은 이식 절차 비용의 증가, 장기 이식에 대한 인식 부족 및 환자가 이식된 장기를 받는 동안 수반되는 위험입니다.
- On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the Middle East and Africa prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the Middle East and Africa prophylaxis of organ rejection market. There are recent developments related to the Middle East and Africa prophylaxis of organ rejection market. The Middle East and Africa prophylaxis of organ rejection market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Prophylaxis of Organ Rejection Market Scope and Market Size
Middle East and Africa prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
- On the basis of cause, the Middle East and Africa prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in U.A.E
- On the basis of treatment, the Middle East and Africa prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and availability of cyclosporine.
- On the basis of route of administration, the Middle East and Africa prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
- On the basis of organ, the Middle East and Africa prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
- 환자 유형에 따라 중동 및 아프리카 장기 거부 예방 시장은 소아와 성인으로 세분화됩니다. 2022년에는 성인 세그먼트가 중동 및 아프리카 장기 거부 예방 시장을 지배할 것으로 예상됩니다. 이는 성인 환자의 만성 질환 및 유전적 상태의 유병률 증가, 성인의 면역 체계 약화, 성인 수혜자 대기자 명단이 어린이 및 여성의 대기자 명단보다 많기 때문입니다.
- 최종 사용자를 기준으로 중동 및 아프리카 장기 거부 예방 시장은 병원, 진료소, 가정 의료 및 기타로 세분화됩니다. 2022년에는 의료 서비스 증가와 기증 장기를 수혜 환자에게 전달하기 위한 중동 및 아프리카의 다른 병원과의 협력으로 인해 병원 부문이 중동 및 아프리카 장기 거부 예방 시장을 지배할 것으로 예상됩니다.
- 유통 채널을 기준으로 중동 및 아프리카 장기 거부 예방 시장은 직접 입찰, 약국 매장 및 기타로 세분화됩니다. 2022년에는 제약 회사의 외래 면역 억제제 수요 급증과 보장된 지불로 인해 직접 입찰 부문이 중동 및 아프리카 장기 거부 예방 시장을 지배할 것으로 예상되며, 시장을 지배할 것으로 예상됩니다.
중동 및 아프리카 장기 거부 예방 시장 국가 수준 분석
중동 및 아프리카의 장기 거부 반응 예방 시장은 원인, 치료, 투여 경로, 장기, 환자 유형, 최종 사용자 및 유통 채널의 7개 부문으로 분류됩니다.
중동 및 아프리카 장기 거부 반응 예방 시장 보고서에서 다루는 국가는 남아프리카공화국, 사우디아라비아, UAE, 이집트, 이스라엘 및 기타 중동과 아프리카 국가입니다.
중동 및 아프리카는 2021년에서 2029년의 예측 기간 동안 상당한 성장률로 성장할 것으로 예상되는데, 중동 및 아프리카 국가들은 주요 개발도상국이며 제약 및 바이오기술 분야에서 R&D 활동을 늘리고 아웃소싱 서비스를 늘리는 데 중점을 두고 있기 때문입니다. 남아프리카는 중동 및 아프리카 시장에서 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
신흥 경제권에서의 장기 거부 반응 예방에 대한 성장 잠재력과 시장 참여자들의 전략적 이니셔티브는 중동 및 아프리카에서 클린룸을 통한 장기 거부 반응 예방 시장에서 새로운 기회를 창출하고 있습니다.
중동 및 아프리카 장기 거부 예방은 또한 클린룸 입자 계수기 판매, 규제 시나리오에서 장기 거부의 진전이 중동 및 아프리카 장기 거부 예방 시장에 대한 지원과 함께 특정 산업에서 모든 국가의 성장에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2020년에서 2021년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 중동 및 아프리카 장기 거부 예방 시장: 점유율 분석
중동 및 아프리카 장기 거부 예방 경쟁 환경은 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 분야 우세, 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 청정실 입자 계수기 시장과 관련된 회사의 초점에만 관련이 있습니다.
중동 및 아프리카에서 장기 거부 반응 예방 서비스를 제공하는 주요 회사로는 Panacea Biotec, WOCKHARDT, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy's Laboratories, Ltd, Viatris Inc, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited, Hikma Pharmaceuticals PLC, AbbVie Inc., Apotex Inc, Zydus Pharmaceuticals, Inc, CSL Behring 등이 있습니다.
시장 참여자들의 전략적 이니셔티브와 장기 거부 반응 예방을 위한 새로운 기술 발전은 장기 이식을 위한 격차를 메웁니다.
예를 들어,
- 2020년 11월, Concord Biotech와 Lupin은 제네릭 면역억제제 캡슐에 대한 미국 FDA 승인을 받았습니다. 승인은 장기 거부에 사용되는 면역억제제 캡슐의 판매를 늘릴 것입니다.
시장 참여자의 협력, 합작투자 및 기타 전략은 중동 및 아프리카 지역의 장기 거부 반응 예방 기업 시장을 확대하고 있으며, 이를 통해 기업은 치료 제품에 대한 제공을 개선하는 데 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 BY CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS
5.1.2 RISE IN CHRONIC DISEASES
5.1.3 RISE IN CLINICAL TRIALS
5.1.4 RISE IN RECIPIENT PATIENTS
5.1.5 PRODUCT APPROVALS
5.2 RESTRAINTS
5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE
5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION
5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN
5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION
5.3 OPPORTUNITIES
5.3.1 RISE IN RESEARCH AND DEVELOPMENTS
5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT
5.4 CHALLENGES
5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION
5.4.2 STRINGENT REGULATIONS
6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE
6.1 OVERVIEW
6.2 EPIDEMIOLOGIC EXPOSURE
6.2.1 HOSPITAL EXPOSURE
6.2.2 COMMUNITY EXPOSURE
6.3 ANTIBACTERIAL PROPHYLAXIS
6.3.1 POST-TRANSPLANT PROPHYLAXIS
6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS
6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS
6.5 OTHERS
7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 OUTPATIENT IMMUNOSUPPRESSANT
7.2.1 CALCINEURIN INHIBITORS
7.2.1.1 CYCLOSPORINE
7.2.1.2 TACROLIMUS
7.2.1.2.1 IMMEDIATE RELEASE
7.2.1.2.2 EXTENDED RELEASE
7.2.2 CORTICOSTEROIDS
7.2.2.1 METHYLPREDNISOLONE
7.2.2.2 PREDNISONE
7.2.2.3 OTHERS
7.2.3 MYCOPHENOLIC ACIDS
7.2.3.1 MYCOPHENOLATE MOFETIL
7.2.3.2 MYCOPHENOLATE SODIUM
7.2.4 MTOR INHIBITORS
7.2.4.1 SIROLIMUS
7.2.4.2 EVEROLIMUS
7.2.5 AZATHIOPRINE
7.2.6 OTHERS
7.3 INPATIENT IMMUNOSUPPRESSANT
7.3.1 BELATACEPT
7.3.2 BASILIXIMAB
7.3.3 OTHERS
7.4 OTHERS
7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS
7.4.1.1 ERYTHROPOIETIN
7.4.1.2 DARBEPOETIN
7.4.2 ANTI-VIRAL AGENTS
7.4.2.1 VALGANCICLOVIR
7.4.2.2 LAMIVUDINE
7.4.2.3 ADEFOVIR
7.4.2.4 OTHERS
7.4.3 OTHERS
8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.2.1 TABLET
8.2.1.1 IMMEDIATE RELEASE
8.2.1.2 EXTENDED-RELEASE
8.2.2 ORAL SOLUTION
8.2.3 OTHERS
8.3 INTRAVENOUS
9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN
9.1 OVERVIEW
9.2 KIDNEY
9.3 LIVER
9.4 HEART
9.5 LUNG
9.6 OTHERS
10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 PEDIATRIC
11 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 HOME HEALTHCARE
11.5 OTHERS
12 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 PHARMACY STORES
12.3.1 HOSPITAL PHARMACY
12.3.2 RETAIL PHARMACY
12.3.3 ONLINE PHARMACY
12.4 OTHERS
13 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SAUDI ARABIA
13.1.2 SOUTH AFRICA
13.1.3 ISRAEL
13.1.4 KUWAIT
13.1.5 U.A.E
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 SAUDI ARABIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 SAUDI ARABIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 SAUDI ARABIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 SAUDI ARABIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 SAUDI ARABIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 SAUDI ARABIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH AFRICA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH AFRICA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 SOUTH AFRICAPROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 SOUTH AFRICA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 SOUTH AFRICA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 97 SOUTH AFRICA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 98 SOUTH AFRICA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 99 SOUTH AFRICA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 100 SOUTH AFRICA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 SOUTH AFRICA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 SOUTH AFRICA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 SOUTH AFRICA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 SOUTH AFRICA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 SOUTH AFRICA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 SOUTH AFRICA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 109 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 SOUTH AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 112 SOUTH AFRICA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 ISRAEL ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 126 ISRAEL ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 127 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 ISRAEL ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 129 ISRAEL TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 130 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 131 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 ISRAEL PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 ISRAEL PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 137 KUWAIT ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 138 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 139 KUWAIT OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 142 KUWAIT MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 143 KUWAIT MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 146 KUWAIT OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 147 KUWAIT ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 KUWAIT ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 KUWAIT TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 152 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 153 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 154 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 KUWAIT PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 KUWAIT PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 158 U.A.E EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 159 U.A.E ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 160 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 U.A.E OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 162 U.A.E CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 163 U.A.E TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 U.A.E MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 165 U.A.E MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 166 U.A.E CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 167 U.A.E INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 168 U.A.E OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 169 U.A.E ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 170 U.A.E ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 171 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 172 U.A.E ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 U.A.E TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)
TABLE 175 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 176 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 U.A.E PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 178 U.A.E PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 179 REST OF MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029
FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021
FIGURE 16 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021
FIGURE 17 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT
FIGURE 18 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET
FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020
FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE MIDDLE EAST & AFRICA SCENARIO, 2020
FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020
FIGURE 23 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021
FIGURE 24 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021
FIGURE 28 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021
FIGURE 36 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021
FIGURE 40 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 42 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021
FIGURE 44 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 45 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 46 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 48 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 49 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 50 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: SNAPSHOT (2021)
FIGURE 52 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021)
FIGURE 53 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 54 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 55 MIDDLE EAST AND AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE (2022-2029)
FIGURE 56 MIDDLE EAST & AFRICA PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
